Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Valuation

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscie...

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) currently trades at a P/E ratio of 0.10 (historical range: 0.09–0.10, median: 0.10), placing it at the 69th percentile — above its historical average, EV/EBITDA of 7.68 (range: 7.68–7.69, 69th percentile).

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) appears slightly overvalued relative to its historical range, with most valuation metrics above their median levels.